CLINICA 100 TOP 10: Abbott Labs
This article was originally published in Clinica
Abbott Labs has moved up one position from last year to No 8 in our Clinica 100 list*. It remains at No 4 in both the IVD and Cardiology lists. Abbott has not made any big M&A deals in 2014/2015, looking instead to build its cardiovascular business with promising technologies that gives it access to fast-growing emerging segments. In 2014, it moved into the electrophysiology space for the first time with the acquisition of ablation mapping specialist Topera Medical. It also secured the rights to buy at a later date Advanced Cardiac Therapeutics, which is sdeveloping an irrigated radiofrequency ablation catheter technology.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.